Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies

Shigdar, Sarah, Ward, Alister C., De, Abhijit, Yang, Chaoyong J., Wei, Mingqian and Duan, Wei 2011, Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies, British journal of haematology, vol. 155, no. 1, pp. 3-13, doi: 10.1111/j.1365-2141.2011.08807.x.

Attached Files
Name Description MIMEType Size Downloads

Title Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies
Author(s) Shigdar, SarahORCID iD for Shigdar, Sarah
Ward, Alister C.ORCID iD for Ward, Alister C.
De, Abhijit
Yang, Chaoyong J.
Wei, Mingqian
Duan, WeiORCID iD for Duan, Wei
Journal name British journal of haematology
Volume number 155
Issue number 1
Start page 3
End page 13
Total pages 11
Publisher Wiley - Blackwell Publishing
Place of publication Oxford, U. K.
Publication date 2011-10
ISSN 0007-1048
Keyword(s) aptamers
nucleic acid-based therapeutics
targeted therapeutics
Summary Haematological malignancies result from a heterogeneous mix of genetic mutations and chromosome aberrations and translocations. Targeted therapies, such as the anti-CD20 antibody rituximab, or the BCR-ABL1 inhibitor imatinib, have proven to be effective treatments in the management of some of these malignancies, though relapsing or refractory disease is still common. Nucleic acid-based therapies have also entered the clinical arena, providing an alternative, complementary approach. The forerunner of these therapies were the antisense oligonucleotides, but their scope has expanded to include short-interfering RNA (siRNA), microRNA, decoy oligonucleotides and aptamers. These can be used either as monotherapeutics, in conjunction with current chemotherapy regimens, or in combination with each other to improve therapeutic efficacy. Not only can these nucleic acid-based therapies silence target genes, they also have the potential of restoring gene function. While challenges remain in delivering effective doses of nucleic acid in vivo, these are steadily being met, suggesting an optimistic future in the treatment of haematological malignancies. This review summarizes the application of nucleic acid-based therapeutics, particularly aptamers, in the diagnosis and treatment of haematological malignancies.
Notes Article first published online 2nd August 2011
Language eng
DOI 10.1111/j.1365-2141.2011.08807.x
Field of Research 111204 Cancer Therapy (excl Chemotherapy and Radiation Therapy)
Socio Economic Objective 920101 Blood Disorders
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Grant ID NHMRC 479505
Copyright notice ©2011, Blackwell Publishing Ltd.
Persistent URL

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 19 times in TR Web of Science
Scopus Citation Count Cited 19 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 412 Abstract Views, 3 File Downloads  -  Detailed Statistics
Created: Wed, 22 Feb 2012, 11:09:30 EST by Jane Moschetti

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact